SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region.
No risks detected for SOM from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$2.62|
|52 Week High||AU$1.73|
|52 Week Low||AU$2.55|
|1 Month Change||11.49%|
|3 Month Change||12.45%|
|1 Year Change||27.81%|
|3 Year Change||55.03%|
|5 Year Change||-34.50%|
|Change since IPO||-72.13%|
Recent News & Updates
Is SomnoMed (ASX:SOM) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|SOM||AU Medical Equipment||AU Market|
Return vs Industry: SOM exceeded the Australian Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: SOM exceeded the Australian Market which returned 24.4% over the past year.
Stable Share Price: SOM is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: SOM's weekly volatility (5%) has been stable over the past year.
About the Company
SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was incorporated in 1987 and is based in Crows Nest, Australia.
SomnoMed Fundamentals Summary
|SOM fundamental statistics|
Is SOM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SOM income statement (TTM)|
|Cost of Revenue||AU$24.96m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.013|
|Net Profit Margin||-1.73%|
How did SOM perform over the long term?See historical performance and comparison
Is SomnoMed undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SOM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SOM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SOM is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: SOM is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SOM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SOM is overvalued based on its PB Ratio (6.7x) compared to the AU Medical Equipment industry average (4.5x).
How is SomnoMed forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SOM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: SOM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SOM's is expected to become profitable in the next 3 years.
Revenue vs Market: SOM's revenue (14.4% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: SOM's revenue (14.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SOM's Return on Equity is forecast to be low in 3 years time (12.4%).
How has SomnoMed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SOM is currently unprofitable.
Growing Profit Margin: SOM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SOM is unprofitable, but has reduced losses over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare SOM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SOM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: SOM has a negative Return on Equity (-3.37%), as it is currently unprofitable.
How is SomnoMed's financial position?
Financial Position Analysis
Short Term Liabilities: SOM's short term assets (A$34.1M) exceed its short term liabilities (A$16.2M).
Long Term Liabilities: SOM's short term assets (A$34.1M) exceed its long term liabilities (A$7.8M).
Debt to Equity History and Analysis
Debt Level: SOM's debt to equity ratio (7.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if SOM's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SOM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SOM has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 9.4% each year
What is SomnoMed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SOM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SOM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SOM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SOM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SOM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Neil Verdal-Austin serves as a Managing Director and Director at SomnoMed Limited since August 24, 2020. He has been the Global Chief Executive of SomnoMed Limited since November 19, 2018. Mr. Verdal-A...
CEO Compensation Analysis
Compensation vs Market: Neil's total compensation ($USD502.08K) is about average for companies of similar size in the Australian market ($USD554.70K).
Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.
Experienced Management: SOM's management team is considered experienced (2.5 years average tenure).
Experienced Board: SOM's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SOM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SomnoMed Limited's employee growth, exchange listings and data sources
- Name: SomnoMed Limited
- Ticker: SOM
- Exchange: ASX
- Founded: 1987
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$202.760m
- Shares outstanding: 82.76m
- Website: https://somnomed.com/au/
Number of Employees
- SomnoMed Limited
- 20 Clarke Street
- Level 3
- Crows Nest
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:02|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.